ARCHIVES

IMRT Less Toxic Than 3D-CRT In Localized Prostate Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

ODAC Advises Approval Of Tamoxifen For Male Breast Cancer Treatment

November 27, 1992

Guest Editorial: The Walue of Quality of Life Data In Judging Patient Benefit: experts Respond To ODAC

September 3, 1999

Roche Reports New Avastin Results As FDA Mulls Breast Cancer Indication.

February 15, 2008

TA To Release Report On Burton Therapy Requested By Congress

February 9, 1990

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

August 31, 1979